ChathamProfessor of Medicine
Louis W. Heck Clinical Scholar
Clinical Director, Division of Clinical Immunology & Rheumatology



Faculty Office Tower (FOT), Room 858
510 20th Street South

Telephone: (205) 996-5602



BSE, Biomedical Engineering, Duke University, 1976
MD, Vanderbilt University, 1980
Internship and Residency, Internal Medicine, University of North Carolina Hospital, Chapel Hill, NC, 1980-1983
Fellowship,Rheumatology, University of Alabama at Birmingham, 1986-1989


Clinical Interests

  • Lupus
  • Immunodeficiency-associated rheumatic disease
  • Sarcoidosis
  • Auto-inflammatory and macrophage activation syndromes


Research Description

Dr. Chatham's research program is focused on the biology of TNF family receptors and their ligands (including BLyS/BAFF) as these relate to disease expression in lupus and other inflammatory/autoimmune disorders. The therapeutic implication of these studies has been extended to current clinical studies that involve the use of monoclonal reagents and soluble receptors targeting BlyS/BAFF in patients with active systemic  lupus as well as their potential use in autoimmunity associated with immunodeficiency. Additional collaborative studies are examining the biology of type-1 interferons and  interferon-alpha blocking reagents on disease activity in systemic lupus and macrophage activation disorders.



Click here for a more complete list of publications. Below are a few selected papers.

Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A. 2012. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum. 64(12):4040-7. PMID:22932861

Nahm MH, Chatham WW, Benjamin WH Jr. 2012. Device for carrying blood samples at 37°C for cryoglobulin test. Clin Vaccine Immunol. 19(9):1555-6. PMID:22815150 

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group. 2012. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 39(8):1632-40. PMID:22707609

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 64(5):625-39. PMID:22473917

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group. 2012. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64(7):2328-37. PMID:22275291 PMCID:PMC3350827

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63(12):3918-30. PMID:22127708

Crowder RN, Zhao H, Chatham WW, Zhou T, Carter RH. 2011. B lymphocytes are resistant to death receptor 5-induced apoptosis. Clin Immunol. 139(1):21-31. PMID: 21276756

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. 2010. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 363(3):221-32. PMID: 20647199

American College of Rheumatology Pain Management Task Force. 2010. Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res (Hoboken). 62(5):590-9. PMID: 20461782

Chatham W.
2010. Rheumatic manifestations of systemic disease: sarcoidosis. Curr Opin Rheumatol. 22(1):85-90. PMID: 19851109

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. 2009. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61(9):1143-51. PMID: 19714615.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. 2009. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61(9):1168-78. PMID: 19714604.

Xu X, Hsu HC, Chen J, Grizzle WE, Chatham WW, Stockard CR, Wu Q, Yang PA, Holers VM, Mountz JD. 2009. Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis. Scand J Immunol. 70(3):309-16. PMID: 19703021.

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J. 2009.
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 119(6):1668-77. PMID: 19478457.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology. 2008. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6):762-84. PMID: 18512708


SOM Epilogue Menu